NCT02860650View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

January 31, 2018

Conditions
Healthy
Interventions
BIOLOGICAL

Ad26.Filo

Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).

BIOLOGICAL

MVA-BN-Filo

MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).

BIOLOGICAL

Ad26.ZEBOV

Ad26.ZEBOV intramuscular (IM) injection at a dose of 5\*10\^10 vp.

BIOLOGICAL

Placebo

IM injection of 0.9 percent saline.

BIOLOGICAL

MVA-BN-Filo

MVA-BN-Filo intramuscular (IM) injection at a dose of 1\*10\^8 Inf U.

Trial Locations (1)

Unknown

Rockville

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT02860650 - A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults | Biotech Hunter | Biotech Hunter